Accessibility Menu
PMV Pharmaceuticals logo

PMV Pharmaceuticals(NASDAQ) PMVP

Market Cap$62.40MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-97%
5 Year-97%
1 Year-19%
1 Month-4%
$1.17
+4.46%
+0.05Today
PMV Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 1.172026-08-04
PMV Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+6.36%USD 1.102026-07-28
1 month-4.1%USD 1.222026-07-02
3 month-19.31%USD 1.452026-05-06
Year to date-6.4%USD 1.252025-12-31
1 year-18.75%USD 1.442025-08-04
3 year-82.27%USD 6.602023-08-04
5 year-96.79%USD 36.452021-08-05
Since inception-97.01%USD 37.512020-09-25

PMV Pharmaceuticals Financials at a Glance

Market Cap

$62.40MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$78.34M

EPS (TTM)

-$1.48

P/E Ratio

-0.79

Dividend

$0.00

Beta (Volatility)

1.19 (Average)

Price

$1.17

Volume

34,455.852

Open

$1.18

Previous Close

$1.17

Daily Range

$1.17 - $1.19

52-Week Range

$1.02 - $1.88

Estimated Earnings Date

Aug 6, 2026

PMVP News

Foolcom-Featured.png

PMV Pharmaceuticals (PMVP) Q2 Loss Jumps

Motley Fool Markets TeamAug 7, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About PMV Pharmaceuticals

PMV Pharmaceuticals develops medicines for people with certain cancer gene mutations. Its main drug aims to fix a faulty protein found in many tumors.

What’s in the PMV Toolbox?

  • Rezatapopt (PC14586): Experimental drug for cancers with the p53 Y220C mutation; no revenue generated yet.
  • Mutant p53 Programs: Research on other p53 mutations, including R282W and R273H, for future therapies.
  • Wild-type p53 Induced-Phosphatase: Early-stage research to restore normal p53 protein function in cancer cells.
  • Investigator-Initiated Studies: Collaborations with cancer centers to test drugs in blood cancers like AML and MDS.

PMV’s Growth Spurt: The Highlights Reel

  • Went public in 2020, raising capital for research and development.
  • Launched Phase 2 trial for rezatapopt in early 2024.
  • Formed research partnerships with MD Anderson and Memorial Sloan Kettering in 2024.
  • Streamlined operations with a 30% workforce reduction in January 2024.
  • Relocated headquarters and lab space in 2024 to reduce costs.

Why PMV Is a Bit Different

Five Things You Need to Know

  • No product revenue in Q2 2025, Q2 2024, or Q2 2023.
  • Net loss was $21 million in Q2 2025, up 1648.6% from Q2 2024.
  • Cash and investments were $55 million in Q2 2025, down 32.2% year-over-year.
  • Research and development expenses rose 25.8% to $18.4 million in Q2 2025.
  • Operating cash outflow was $18 million in Q2 2025, up 1045.3% from Q2 2024.

Bottom Line

The company remains in early development, with no product sales and ongoing research costs.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

54

CEO

David H. Mack, PhD

Website

www.pmvpharma.com

Headquarters

Princeton, NJ 08540, US

PMVP Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-68.98%

Return on Capital

-81.67%

Return on Assets

-81.13%

Earnings Yield

-1.27%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$62.40MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

53.33M

Volume

34.46K

Avg. Volume

367.30K

Financials (TTM)

Gross Profit

-$66.00K

Operating Income

-$83.66M

EBITDA

-$78.19M

Operating Cash Flow

-$74.99M

Capital Expenditure

-$25.00K

Free Cash Flow

-$75.02M

Cash & ST Invst.

$93.55M

Total Debt

$293.00K

PMV Pharmaceuticals Performance Analysis

PMV Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
PMV Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
PMV Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.6125.5%
20232023-12-31USD -1.44-10.7%
20242024-12-31USD -1.14-20.7%
20252025-12-31USD -1.4830.0%
PMV Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-20.6%
Q32025-09-302.4%
Q42025-12-3115.0%
Q12026-03-31N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$34.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$62.40MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.16M

N/A

Employees

54

N/A

Net Income

-$18.04M

-3.5%

EBITDA

-$18.00M

+8.1%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$93.55M

-41.7%

Total Debt

$293.00K

-73.5%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$293.00K

-19.5%

Return on Assets

-81.13%

N/A

Return on Invested Capital

-95.11%

N/A

Free Cash Flow

-$19.68M

-7.7%

Operating Cash Flow

-$19.68M

-7.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ACRVAcrivon Therapeutics, Inc. Common Stock
$1.62+3.85%
ATYRaTyr Pharma, Inc.
$0.51-3.93%
TCRXTScan Therapeutics, Inc.
$0.76+3.07%
CBUSCibus, Inc.
$1.90-1.04%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$115.61-0.08%
NVDANvidia
$220.18+0.04%
YXTYxt.com Group
$7.76+1.98%
INLFInlif
$6.01+0.89%

Questions About PMVP

What is the current price of PMV Pharmaceuticals?

PMV Pharmaceuticals is trading at $1.17 per share.

What is the 52-week range for PMV Pharmaceuticals?

Over the past 52 weeks, PMV Pharmaceuticals has traded between $1.02 and $1.88.

How much debt does PMV Pharmaceuticals have?

As of the most recent reporting period, PMV Pharmaceuticals reported total debt of $293.00K.

How much cash does PMV Pharmaceuticals have on hand?

PMV Pharmaceuticals reported $39.13M in cash and cash equivalents in its most recent financial results.

What is PMV Pharmaceuticals’s dividend yield?

PMV Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services